Ideally, targets should only be found tumor cells across a broad spectrum of cancers. Conventionally, they’re often dirty – found on tumors and healthy cells.

The lack of suitable cancer targets has kept today’s advanced therapeutic modalities – including T-cell bispecific antibodies, ADCs, CAR-T, and immunomodulators – from delivering their full potential to most solid tumor patients. GO’s innovative science bridges this gap with novel, super-clean targets that will become the framework for the next wave of cancer therapies.

Go for clean cancer targets

Fueling the future of solid tumor therapies

GO’s validated discovery platform finds the novel, super-clean targets – and the antibodies against them – needed to unleash the next wave of solid tumor therapies.

Our Science